Side-by-side · Research reference
GHK-CuvsKPV
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticReviewed8/47 cited
BAnimal-StrongDraft13/39 cited
GHK-Cu
Tripeptide · Skin / Hair / Wound Healing
SQ or topical · Local · Daily or 2-3×/week
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
01Mechanism of Action
Parameter
GHK-Cu
KPV
Primary target
Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Pathway
Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Downstream effect
Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018Zink 2003
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Feedback intact?
Replaces declining endogenous levels
No melanocortin receptor binding
Origin
Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Antibody development
—
—
02Dosage Protocols
Parameter
GHK-Cu
KPV
Standard SQ dose
1–2 mg / dayPickart 2018
Anecdotal injectable range; topical creams use 0.1–2% solutions.
—
Topical concentration
0.1–2.0% in serum / cream
—
Frequency
Daily or 2–3× per week (SQ)
Daily or 2–3× per week
Lower / starter dose
0.5 mg / day SQ
100 mcg / day
Evidence basis
Human-mechanistic + topical clinical studiesPickart 2018
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Duration
8–12 weeks for visible skin / hair effect
4–8 weeks per cycle
Reconstitution
Bacteriostatic water; light-protected
Bacteriostatic water (SQ form)
Timing
No specific time; evening preferred for topicals
No specific time; often taken with / before meals (oral)
Half-life
Hours (estimated; rapid tissue uptake)
Hours (estimated; rapid tissue uptake)
04Side Effects & Safety
Parameter
GHK-Cu
KPV
Injection site reaction
Erythema, mild pruritus (common)
Mild irritation
Topical irritation
Mild redness, transient stinging
—
Copper accumulation
Theoretical with very high chronic doses
—
Allergic reaction
Rare hypersensitivity to copper
—
Pregnancy / OB
Avoid topical and SQ — insufficient data
Avoid — insufficient data
Wilson disease
Contraindicated
—
GI symptoms
—
Rare nausea (oral form)
Long-term safety
—
Limited human data
Absolute Contraindications
GHK-Cu
- ·Wilson disease (copper-overload disorder)
- ·Pregnancy / breastfeeding
- ·Known copper hypersensitivity
KPV
- ·Pregnancy / breastfeeding
Relative Contraindications
GHK-Cu
- ·Hemochromatosis (copper-iron crosstalk theoretical)
- ·Concurrent copper-chelator therapy
KPV
- ·Active autoimmune disease (theoretical)
05Administration Protocol
Parameter
GHK-Cu
KPV
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.
Add 1 mL bacteriostatic water to vial per labelling.
2. Injection site
SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
3. Timing
Anytime; evening preferred. Topical: apply to clean dry skin.
Morning preferred; oral form taken with / before meals.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.
29–31G insulin syringe (SQ form).
06Stack Synergy
GHK-Cu
+ BPC-157
ModerateGHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.
- GHK-Cu
- 1–2 mg SQ · daily near wound
- BPC-157
- 250–500 mcg SQ · daily near wound
- Primary benefit
- Combined ECM rebuilding + angiogenesis for tissue repair
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions